| Attribute |
Value |
| 52 Week Change |
1.8783422 |
| Address1 |
1,800 Sierra Point Parkway |
| Address2 |
Suite 200 |
| All Time High |
28.699 |
| All Time Low |
5.44 |
| Ask |
27.5 |
| Ask Size |
200 |
| Audit Risk |
6 |
| Average Daily Volume10 Day |
1,339,586 |
| Average Volume |
3,997,528 |
| Average Volume10Days |
1,339,586 |
| Beta |
-1.748 |
| Bid |
15.47 |
| Bid Size |
200 |
| Board Risk |
5 |
| Book Value |
4.284 |
| City |
Brisbane |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Compensation Risk |
8 |
| Country |
United States |
| Currency |
USD |
| Current Price |
21.53 |
| Current Ratio |
8.015 |
| Date Short Interest |
1,776,211,200 |
| Day High |
21.53 |
| Day Low |
21.49 |
| Debt To Equity |
0.633 |
| Ebitda |
-124,274,000 |
| Ebitda Margins |
-0.78564 |
| Enterprise To Ebitda |
-14.369 |
| Enterprise To Revenue |
11.289 |
| Enterprise Value |
1,785,679,232 |
| Exchange |
NMS |
| Exchange Timezone Name |
UTC |
| Fifty Day Average |
18.6268 |
| Fifty Two Week High |
21.53 |
| Fifty Two Week Low |
5.635 |
| Financial Currency |
USD |
| First Trade Date Epoch Utc |
1,622,122,200 |
| Float Shares |
71,347,715 |
| Forward Eps |
-0.12125 |
| Forward P E |
-504.09744 |
| Free Cashflow |
-61,958,752 |
| Full Time Employees |
178 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Governance Epoch Date |
1,775,001,600 |
| Gross Margins |
0.8912 |
| Gross Profits |
140,972,000 |
| Held Percent Insiders |
0.16820998 |
| Held Percent Institutions |
0.83489 |
| Implied Shares Outstanding |
103,334,169 |
| Industry |
Biotechnology |
| Industry Disp |
Biotechnology |
| Industry Key |
biotechnology |
| Last Fiscal Year End |
1,767,139,200 |
| Long Business Summary |
Day One Biopharmaceuticals, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral and brain-penetrant type II rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It is also developing DAY301, a PTK7 targeted ADC composed of a novel humanized anti-PTK7 immunoglobulin G1 monoclonal antibody conjugated with a topoisomerase I inhibitor via a highly stable and hydrophilic modified valine-alanine (VA) cleavable linker for the treatment of patients with advanced solid tumors; and Emi-Le, an antibody-drug conjugate that targets B7- H4 conjugated to an auristatin anti-tubulin payload as a component of a proprietary linker-payload platform developed by Mersana Therapeutics that is in Phase 1 clinicla trial for the treatment of breast cancer, ovarian cancer, endometrial cancer, and adenoid cystic carcinoma (ACC). Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California. As of April 22, 2026, Day One Biopharmaceuticals, Inc. operates as a subsidiary of Servier Pharmaceuticals LLC. |
| Long Name |
Day One Biopharmaceuticals Inc |
| Market Cap |
2,224,784,640 |
| Max Age |
86,400 |
| Message Board Id |
finmb_704589075 |
| Most Recent Quarter |
1,767,139,200 |
| Net Income To Common |
-107,322,000 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
2,224,784,658 |
| Number Of Analyst Opinions |
6 |
| Open |
21.49 |
| Operating Cashflow |
-103,757,000 |
| Operating Margins |
-0.51115 |
| Overall Risk |
7 |
| Payout Ratio |
0.0 |
| Phone |
650 484 0899 |
| Previous Close |
0.0 |
| Price Hint |
2 |
| Price To Book |
5.025677 |
| Price To Sales Trailing12 Months |
14.064714 |
| Profit Margins |
-0.67847 |
| Quick Ratio |
7.73 |
| Quote Type |
EQUITY |
| Recommendation Key |
none |
| Regular Market Day High |
21.53 |
| Regular Market Day Low |
21.49 |
| Regular Market Open |
21.49 |
| Regular Market Previous Close |
0.0 |
| Regular Market Volume |
2,671,205 |
| Return On Assets |
-0.14642 |
| Return On Equity |
-0.2274 |
| Revenue Growth |
0.839 |
| Revenue Per Share |
1.533 |
| Sand P52 Week Change |
0.1982081 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Share Holder Rights Risk |
8 |
| Shares Outstanding |
103,334,169 |
| Shares Percent Shares Out |
0.0637 |
| Shares Short |
6,579,076 |
| Shares Short Previous Month Date |
1,773,360,000 |
| Shares Short Prior Month |
8,091,418 |
| Short Name |
Day One Biopharmaceuticals, Inc |
| Short Percent Of Float |
0.0749 |
| Short Ratio |
2.79 |
| State |
CA |
| Symbol |
DAWN |
| Target High Price |
21.5 |
| Target Low Price |
21.5 |
| Target Mean Price |
21.5 |
| Target Median Price |
21.5 |
| Time Zone Full Name |
America/New_York |
| Time Zone Short Name |
EDT |
| Total Cash |
441,112,992 |
| Total Cash Per Share |
4.27 |
| Total Debt |
2,793,000 |
| Total Revenue |
158,182,000 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.0 |
| Trailing Annual Dividend Yield |
NaN |
| Trailing Eps |
-1.04 |
| Trailing Peg Ratio |
None |
| Two Hundred Day Average |
10.955325 |
| Underlying Symbol |
DAWN |
| Uuid |
a17405a3-1622-35cb-92a5-67defd12b1ed |
| Volume |
2,671,205 |
| Website |
https://dayonebio.com |
| Zip |
94,005 |